循环酸盐在末期肝病患者中可逆升高:与全因死亡率的关联
Yakun Li1, Mateo Chvatal-Medina1, Maria Camila Trillos-Almanza1
1Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands.
International journal of molecular sciences
|December 17, 2024
概括
在末期肝病 (ESLD) 患者中,循环酸盐水平升高,在移植后降低. 高酸盐与ESLD的死亡风险增加有关,特别是在男性中.
科学领域:
- 生物化学 生物化学
- 线粒体生物学 线粒体生物学
- 肝病学 肝病学是一种肝病学.
背景情况:
- 线粒体功能障碍与末期肝病 (ESLD) 的进展有关.
- 循环中的酸盐可能表明线粒体功能障碍.
研究的目的:
- 在ESLD患者中量化循环酸盐水平.
- 评估等待肝移植的ESLD患者中酸盐水平与死亡率之间的关联.
主要方法:
- 通过核磁共振光谱测量了等离子 citrate.
- 129名ESLD患者 (TransplantLines队列) 与4837名对照组 (PREVEND队列) 相比.
- 在肝移植前和之后分析的酸盐水平在一个子集中.
主要成果:
- 与对照组相比,ESLD患者的血酸盐含量高出40% (p < 0.001).
- 移植后的酸盐水平显著下降 (p < 0.001).
- 较高的酸盐与较高的查尔德-图尔科特-普希得分和较低的EGFR (p <0.05) 相相关.
- 与降低生存率相关的最高酸盐三位数 (日志数排名p = 0.037).
- 与较高的酸盐 (HR: 1.65; p = 0.037) 观察到所有原因的死亡风险增加,特别是在男性中 (HR: 2.04; p = 0.027).
结论:
- 血中酸盐在ESLD患者中升高,并在移植后恢复正常.
- 循环中酸盐的增加是ESLD患者死亡风险增加的潜在生物标志物,特别是在男性中.
相关概念视频
Liver Regeneration
The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
Hepatic Drug Excretion: Enterohepatic Cycling
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Cirrhosis I: Introduction
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...


